TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11127936

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 60
Study: 9133516

Group type: EXPERIMENTAL
Intervention: Exercise group (n=12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (n=13)
Number of subjects: 25
Study: 7697311

Group type: EXPERIMENTAL
Intervention: Art Future Image Intervention (AFI)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 158
Study: 3665957

Group type: EXPERIMENTAL
Intervention: High-dose anticoagulants
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oral warfarin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Post-warfarin discontinuation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Apical akinesis at 10 days
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Patients with LV thrombi
Number of subjects: 21
Study: 29410448

Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Antibiotic use
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Birth mode
Number of subjects: 45
Study: 28070786

Group type: EXPERIMENTAL
Intervention: Volunteer Advocacy Program-Transition (VAP-T)
Number of subjects: 41
Study: 26403905

Group type: EXPERIMENTAL
Intervention: Driver support application with phone blocking (N=92)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Driver support application with phone blocking and parental monitoring (N=90)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group with application recording phone use (N=92)
Number of subjects: 182
Study: 22960586

Group type: EXPERIMENTAL
Intervention: Increasing fluid intake (n = 44)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Maintenance group (n = 30)
Number of subjects: 74
Study: 20969563

Group type: EXPERIMENTAL
Intervention: Aqueous cream
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 50:50 white soft paraffin and liquid paraffin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diprobase(®)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Epaderm(®)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment and cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no topical agent)
Number of subjects: 20
Study: 18280960

Group type: EXPERIMENTAL
Intervention: Distraction Osteogenesis (DO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Inlay Bone Grafting (Inlay)
Number of subjects: 12
Study: 16950289

Group type: EXPERIMENTAL
Intervention: Childhood asthma debut at younger than 5 years
Number of subjects: 9812

Group type: EXPERIMENTAL
Intervention: 3 or more asthma symptoms in adults
Number of subjects: 9812

Group type: EXPERIMENTAL
Intervention: Asthma medication in adults
Number of subjects: 9812

Group type: EXPERIMENTAL
Intervention: Hay fever in adults
Number of subjects: 9812

Group type: EXPERIMENTAL
Intervention: Atopy in adults
Number of subjects: 9812

Group type: EXPERIMENTAL
Intervention: Specific IgE to cat in adults
Number of subjects: 9812

Group type: EXPERIMENTAL
Intervention: Pet removal between surveys to reduce allergen
Number of subjects: 9812
Study: 12661143

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 gram intramuscularly at 24‐hour intervals
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Recurrent urinary tract infection
Number of subjects: 71
Study: 10721928

Group type: EXPERIMENTAL
Intervention: Community-based dietary intervention
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 137
Study: 8845572

Group type: EXPERIMENTAL
Intervention: Induction therapy with melphalan and prednisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with melphalan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance treatment with interferon alpha
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-line treatment for MM patients who are primary refractory to melphalan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy with melphalan and prednisone
Number of subjects: 0
Study: 2079452

Group type: EXPERIMENTAL
Intervention: cefadroxil 1 g tid (13 subjects)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: co‐trimoxazole 160/800 mg bd (23 subjects)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: norfloxacin 400 mg bd (35 subjects)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Overall treatment (all agents)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Patients with adequate mobility and normal renal function
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Overall results for men
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Overall results for women
Number of subjects: 71
Study: 94209

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: PGE2 and serotonin (injected intradermally in healthy volunteers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ADP (in vitro study)
Number of subjects: 0
Study: 31500670

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1.8 g/day for 16 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 28195952

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (n = 58)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Usual care (n = 42)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy and Usual care combined
Number of subjects: 88
Study: 25557936

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unbuffered lidocaine
Number of subjects: 0
Study: 23065349

Group type: EXPERIMENTAL
Intervention: Responsive Classroom® approach (RC)
Number of subjects: 83
Study: 20798665

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI; 15°C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Neutral Water Immersion (NWI; 33°C)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CON; no immersion)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Comparison between CWI and NWI
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Leptin levels
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Active ghrelin levels
Number of subjects: 10
Study: 18991063

Group type: EXPERIMENTAL
Intervention: 10 microg/m(3) UFP exposure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 25 microg/m(3) UFP exposure
Number of subjects: 24

Group type: COMPARATOR
Intervention: Filtered air exposure
Number of subjects: 24
Study: 16817913

Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2b and lamivudine combination
Number of subjects: 88

Group type: COMPARATOR
Intervention: lamivudine monotherapy
Number of subjects: 88
Study: 12956752

Group type: EXPERIMENTAL
Intervention: Active group (environmental control measures including vinyl flooring, allergen-impermeable cot mattress, hot-washable toy, mite allergen-impermeable encasings, high filtration vacuum cleaner)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Active group
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 278
Study: 10706509

Group type: EXPERIMENTAL
Intervention: 150 microg fluticasone propionate (FP) b.i.d. delivered via Babyhaler spacer
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo delivered via Babyhaler spacer
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: FP and placebo groups
Number of subjects: 48
Study: 9153522

Group type: EXPERIMENTAL
Intervention: Patients with progressive supranuclear palsy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Age-matched control subjects
Number of subjects: 10
Study: 8217354

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CMF: cyclophosphamide, methotrexate, and 5-fluorouracil)
Number of subjects: 176

Group type: COMPARATOR
Intervention: No adjuvant therapy (control)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Endocrine treatment after relapse
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Chemotherapy after relapse
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CMF)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (CMF) and No adjuvant therapy (control)
Number of subjects: 176
Study: 3304523

Group type: EXPERIMENTAL
Intervention: Occlusive hydrocolloid dressing (Granuflex, Squibb Surgicare)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Porous non-adherent dressing (N A, Johnson and Johnson)
Number of subjects: 56
Study: 31576565

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Supportive psychotherapy
Number of subjects: 260
Study: 30160521

Group type: EXPERIMENTAL
Intervention: Serum triglycerides
Number of subjects: 5042

Group type: EXPERIMENTAL
Intervention: Top quintile (>185 mg/dl)
Number of subjects: 5042
Study: 27157575

Group type: EXPERIMENTAL
Intervention: Synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (heat-treated fermented milk without probiotic bacteria or dietary fiber)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Synbiotic fermented milk
Number of subjects: 30

Group type: COMPARATOR
Intervention: Synbiotic and placebo
Number of subjects: 30
Study: 24941843

Group type: EXPERIMENTAL
Intervention: Dangfei Liganning Tablet (DLT), two tablets each time, three times per day for 4 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Liver‐protecting Tablet (LT), four tablets each time, three times per day for 4 weeks
Number of subjects: 80
Study: 22502713

Group type: EXPERIMENTAL
Intervention: Psychosocial factors (e.g., agreeableness, extraversion, stress, social support, self-efficacy)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Access to greater social support
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Higher perceived stress
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Provider-patient communication and physical environment
Number of subjects: 1500
Study: 21098355

Group type: EXPERIMENTAL
Intervention: Positive version of the manuscript
Number of subjects: 238

Group type: COMPARATOR
Intervention: No-difference version of the manuscript
Number of subjects: 238
Study: 18482155

Group type: EXPERIMENTAL
Intervention: Naltrexone monotherapy (50 mg naltrexone + sertraline placebo)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Naltrexone + sertraline (100 mg) plus nine sessions of medical management and supportive advice
Number of subjects: 101
Study: 15672052

Group type: EXPERIMENTAL
Intervention: Bowel preparation
Number of subjects: 61

Group type: COMPARATOR
Intervention: No bowel preparation
Number of subjects: 61
Study: 12886816

Group type: EXPERIMENTAL
Intervention: Multimicronutrient supplementation (vitamin A, 1000 micrograms; vitamin B1, 1.4 mg; vitamin B2, 1.6 mg; vitamin B6, 1.7 mg; vitamin B12, 2.0 micrograms; folate, 150 micrograms; niacin, 16 mg; vitamin C, 50 mg; vitamin D, 5 micrograms; vitamin E, 8 mg; iron, 18 mg; zinc, 20 mg; copper, 2.0 mg; iodine, 150 micrograms; selenium, 40 micrograms)
Number of subjects: 977

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 977

Group type: EXPERIMENTAL
Intervention: Multimicronutrient supplementation
Number of subjects: 977
Study: 10229998

Group type: EXPERIMENTAL
Intervention: High-resistance training (12 weeks, 3 times a week, 3 x 10 repetitions at 80% of 1RM)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control leg (no training)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-resistance training
Number of subjects: 9
Study: 8890674

Group type: EXPERIMENTAL
Intervention: Adjunctive medication (lithium, perphenazine, or paroxetine)
Number of subjects: 158

Group type: COMPARATOR
Intervention: No adjunctive medication
Number of subjects: 158
Study: 1422291

Group type: EXPERIMENTAL
Intervention: Xylocaine spray with frigen, two applications (20 mg lidocaine)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Xylestesin spray with frigen, two applications (14 mg lidocaine)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Xylestesin spray with frigen, three applications (21 mg lidocaine)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Xylestesin pump spray without frigen, two applications (14 mg lidocaine)
Number of subjects: 130

Group type: COMPARATOR
Intervention: No topical anesthesia
Number of subjects: 130
Study: 4084667

Group type: EXPERIMENTAL
Intervention: Prednisolone hemisuccinate 1200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisolone hemisuccinate 75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisolone hemisuccinate (both doses)
Number of subjects: 0
Study: 30085292

Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin (40 IU)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 48
Study: 29661241

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT-O)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 27712772

Group type: EXPERIMENTAL
Intervention: Sodium reduction intervention
Number of subjects: 3126

Group type: COMPARATOR
Intervention: Not assigned to an active sodium intervention
Number of subjects: 3126

Group type: EXPERIMENTAL
Intervention: Average sodium intake categories (<2,300, 2,300 to <3,600, 3,600 to <4,800, and ≥4,800 mg/24 h)
Number of subjects: 3126

Group type: EXPERIMENTAL
Intervention: Sodium/potassium ratio
Number of subjects: 3126
Study: 24999963

Group type: EXPERIMENTAL
Intervention: Elevated SDMA (4th quartile, >1.38 μmol/L)
Number of subjects: 925
Study: 23356027

Group type: COMPARATOR
Intervention: 1 year of WHO‐MDT (dapsone, clofazimine, rifampin)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 1 year of WHO‐MDT plus an initial 1 month of daily ofloxacin
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 1 month of daily rifampin and daily ofloxacin
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 2 years of WHO‐MDT
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 1 month of daily rifampicin and daily ofloxacin
Number of subjects: 198
Study: 20228404

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 5518

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5518
Study: 18564278

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dietary treatment alone (Control)
Number of subjects: 40
Study: 16403993

Group type: EXPERIMENTAL
Intervention: Lamotrigine (50-100 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no lamotrigine)
Number of subjects: 30
Study: 14657874

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10937983

Group type: EXPERIMENTAL
Intervention: Low dose lisinopril (2.5-5.0 mg/day)
Number of subjects: 3164

Group type: EXPERIMENTAL
Intervention: High dose lisinopril (32.5-35.0 mg/day)
Number of subjects: 3164

Group type: EXPERIMENTAL
Intervention: All cause mortality (primary endpoint)
Number of subjects: 3164

Group type: EXPERIMENTAL
Intervention: Composite of all-cause hospitalisation or all-cause mortality (secondary endpoint)
Number of subjects: 3164
Study: 8901854

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (50 mg)
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg)
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg) in participants smoking at least 20 cigarettes daily
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg) in participants smoking 5-19 cigarettes daily
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg) in participants with higher alcohol intake (> or = 11 g of ethanol/day)
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg) in participants with lower alcohol intake
Number of subjects: 29133
Study: 2053632

Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 56
Study: 6753891

Group type: EXPERIMENTAL
Intervention: Captopril (25-50 mg three times daily)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Atenolol (50-100 mg once daily)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide (25-50 mg once daily)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Atenolol + Hydrochlorothiazide (25-50 mg once daily)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 57
Study: 31049877

Group type: EXPERIMENTAL
Intervention: Active group (n = 137, 20 g of whey protein, 3 g of leucine, 800 IU VitD)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control group (n = 151, isocaloric control product)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Active group
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 288
Study: 29855307

Group type: EXPERIMENTAL
Intervention: Tailored retinal screening promotion leaflet
Number of subjects: 237
Study: 26411392

Group type: EXPERIMENTAL
Intervention: High-flexion concept posterior-stabilized knee prosthesis (LOSPA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard posterior-stabilized knee prosthesis (P.F.C. Sigma)
Number of subjects: 44
Study: 24913212

Group type: EXPERIMENTAL
Intervention: Exercise Dance for Seniors (EXDASE) Program, performed once a week for 60 minutes for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what the control was)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise Dance for Seniors (EXDASE) Program
Number of subjects: 0
Study: 22207667

Group type: EXPERIMENTAL
Intervention: Education program regarding the nature of temporomandibular disorder (TMD) and self-care measures
Number of subjects: 41

Group type: COMPARATOR
Intervention: Occlusal splint
Number of subjects: 41
Study: 20431381

Group type: EXPERIMENTAL
Intervention: Caspofungin (70 mg/m loading dose on day 1, then 50 mg/m daily, maximum 70 mg/d)
Number of subjects: 82

Group type: COMPARATOR
Intervention: L-AmB (3 mg/kg daily)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 82

Group type: COMPARATOR
Intervention: L-AmB
Number of subjects: 82
Study: 17570804

Group type: EXPERIMENTAL
Intervention: Trial-specific tailored materials
Number of subjects: 118

Group type: COMPARATOR
Intervention: Widely used generic booklet about clinical trials
Number of subjects: 118
Study: 15654776

Group type: EXPERIMENTAL
Intervention: 0.05% crystal violet
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 0.1% crystal violet
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 0.5% methylene blue
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 1.0% methylene blue
Number of subjects: 400
Study: 12138325

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg under fasting conditions
Number of subjects: 18

Group type: COMPARATOR
Intervention: Gatifloxacin 400 mg under fed conditions
Number of subjects: 18
Study: 10457579

Group type: EXPERIMENTAL
Intervention: Mensendieck exercise program (20 group sessions over 13 weeks)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (experience without intervention)
Number of subjects: 77
Study: 7543083

Group type: EXPERIMENTAL
Intervention: 50 mmol magnesium sulfate infusion over 20 hours
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 2475689

Group type: EXPERIMENTAL
Intervention: 240 mg verapamil HCl sustained‐release tablet (Isoptin SR 240, Securon SR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: two half 240‐mg verapamil HCl sustained‐release tablets (2 X half 240‐mg tablets, Study 1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: two 120-mg verapamil HCl sustained‐release tablets (Isoptin SR 120) (2 X 120 mg, Study 2)
Number of subjects: 10
Study: 31808151

Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg.kg-1
Number of subjects: 51

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 51
Study: 29277690

Group type: EXPERIMENTAL
Intervention: Long-acting β2 agonists, long-acting muscarinic antagonists (LABAs or LAMAs), LABA/LAMA combination QVA149
Number of subjects: 23213

Group type: EXPERIMENTAL
Intervention: Active treatments (including LABA/LAMA)
Number of subjects: 23213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23213
Study: 28251729

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 79

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 79
Study: 25644340

Group type: EXPERIMENTAL
Intervention: Whole grain (WG) diet (>80 g/d)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Refined grain (RG) diet (<16 g/d)
Number of subjects: 33
Study: 24325834

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study: 21310691

Group type: EXPERIMENTAL
Intervention: Performed actions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observed actions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active recall during retrieval practice
Number of subjects: 0
Study: 18315425

Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation plus application of an 8.8% doxycycline gel
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ultrasonic instrumentation alone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Adjunctive antibiotic therapy (doxycycline)
Number of subjects: 32
Study: 17195531

Group type: EXPERIMENTAL
Intervention: Xenical (120 mg 3 times a day) with moderate hypocaloric diet
Number of subjects: 75

Group type: COMPARATOR
Intervention: Moderate hypocaloric diet
Number of subjects: 75
Study: 12749501

Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (ITNs)
Number of subjects: 0